Age  ||| S:0 E:4 ||| NN
and  ||| S:4 E:8 ||| CC
indications  ||| S:8 E:20 ||| NNS
to  ||| S:20 E:23 ||| TO
SLIT  ||| S:23 E:28 ||| NNP
Clinical  ||| S:28 E:37 ||| NNP
efficacy  ||| S:37 E:46 ||| NN
of  ||| S:46 E:49 ||| IN
sublingual  ||| S:49 E:60 ||| JJ
immunotherapy  ||| S:60 E:74 ||| NNS
( ||| S:74 E:75 ||| -LRB-
SLIT ||| S:75 E:79 ||| NNP
)  ||| S:79 E:81 ||| -RRB-
has  ||| S:81 E:85 ||| VBZ
been  ||| S:85 E:90 ||| VBN
investigated  ||| S:90 E:103 ||| VBN
during  ||| S:103 E:110 ||| IN
the  ||| S:110 E:114 ||| DT
last  ||| S:114 E:119 ||| JJ
20  ||| S:119 E:122 ||| CD
years  ||| S:122 E:128 ||| NNS
and  ||| S:128 E:132 ||| CC
results  ||| S:132 E:140 ||| NNS
of  ||| S:140 E:143 ||| IN
several  ||| S:143 E:151 ||| JJ
meta-analyses  ||| S:151 E:165 ||| NNS
are  ||| S:165 E:169 ||| VBP
available ||| S:169 E:178 ||| JJ
,  ||| S:178 E:180 ||| ,
showing  ||| S:180 E:188 ||| VBG
clinical  ||| S:188 E:197 ||| JJ
efficacy  ||| S:197 E:206 ||| NN
of  ||| S:206 E:209 ||| IN
SLIT  ||| S:209 E:214 ||| NNP
in  ||| S:214 E:217 ||| IN
children  ||| S:217 E:226 ||| NNS
both  ||| S:226 E:231 ||| CC
in  ||| S:231 E:234 ||| IN
allergic  ||| S:234 E:243 ||| JJ
asthma  ||| S:243 E:250 ||| NN
and  ||| S:250 E:254 ||| CC
in  ||| S:254 E:257 ||| IN
rhinitis ||| S:257 E:265 ||| NN
,  ||| S:265 E:267 ||| ,
but  ||| S:267 E:271 ||| CC
strict  ||| S:271 E:278 ||| JJ
recommendations  ||| S:278 E:294 ||| NNS
are  ||| S:294 E:298 ||| VBP
not  ||| S:298 E:302 ||| RB
possible  ||| S:302 E:311 ||| JJ
under  ||| S:311 E:317 ||| IN
current  ||| S:317 E:325 ||| JJ
evidence ||| S:325 E:333 ||| NN
.  ||| S:333 E:335 ||| .
Minimum  ||| S:335 E:343 ||| JJ
age  ||| S:343 E:347 ||| NN
for  ||| S:347 E:351 ||| IN
starting  ||| S:351 E:360 ||| VBG
SLIT  ||| S:360 E:365 ||| NNP
is  ||| S:365 E:368 ||| VBZ
not  ||| S:368 E:372 ||| RB
clearly  ||| S:372 E:380 ||| RB
defined  ||| S:380 E:388 ||| VBN
but  ||| S:388 E:392 ||| CC
several  ||| S:392 E:400 ||| JJ
position  ||| S:400 E:409 ||| NN
paper  ||| S:409 E:415 ||| NN
and  ||| S:415 E:419 ||| CC
guidelines  ||| S:419 E:430 ||| NNS
indicate  ||| S:430 E:439 ||| VBP
a  ||| S:439 E:441 ||| DT
lower  ||| S:441 E:447 ||| JJR
limit  ||| S:447 E:453 ||| NN
of  ||| S:453 E:456 ||| IN
5  ||| S:456 E:458 ||| CD
years  ||| S:458 E:464 ||| NNS
of  ||| S:464 E:467 ||| IN
age ||| S:467 E:470 ||| NN
.  ||| S:470 E:472 ||| .
Guidelines  ||| S:472 E:483 ||| NNS
on  ||| S:483 E:486 ||| IN
allergic  ||| S:486 E:495 ||| JJ
rhinitis  ||| S:495 E:504 ||| NN
suggests  ||| S:504 E:513 ||| VBZ
SLIT  ||| S:513 E:518 ||| NNP
in  ||| S:518 E:521 ||| IN
patients  ||| S:521 E:530 ||| NNS
not  ||| S:530 E:534 ||| RB
well  ||| S:534 E:539 ||| RB
controlled  ||| S:539 E:550 ||| VBN
with  ||| S:550 E:555 ||| IN
drugs  ||| S:555 E:561 ||| NNS
or  ||| S:561 E:564 ||| CC
those  ||| S:564 E:570 ||| DT
who  ||| S:570 E:574 ||| WP
refuse  ||| S:574 E:581 ||| VBP
to  ||| S:581 E:584 ||| TO
use  ||| S:584 E:588 ||| VB
drugs ||| S:588 E:593 ||| NNS
.  ||| S:593 E:595 ||| .
Additional  ||| S:595 E:606 ||| JJ
effects  ||| S:606 E:614 ||| NNS
are  ||| S:614 E:618 ||| VBP
prevention  ||| S:618 E:629 ||| VBN
of  ||| S:629 E:632 ||| IN
new  ||| S:632 E:636 ||| JJ
sensitizations  ||| S:636 E:651 ||| NNS
( ||| S:651 E:652 ||| -LRB-
evidence  ||| S:652 E:661 ||| NN
IIa ||| S:661 E:664 ||| NN
)  ||| S:664 E:666 ||| -RRB-
and  ||| S:666 E:670 ||| CC
prevention  ||| S:670 E:681 ||| NN
of  ||| S:681 E:684 ||| IN
asthma  ||| S:684 E:691 ||| NN
in  ||| S:691 E:694 ||| IN
patients  ||| S:694 E:703 ||| NNS
with  ||| S:703 E:708 ||| IN
allergic  ||| S:708 E:717 ||| JJ
rhinitis  ||| S:717 E:726 ||| NNS
( ||| S:726 E:727 ||| -LRB-
evidence  ||| S:727 E:736 ||| NN
I  ||| S:736 E:738 ||| PRP
b ||| S:738 E:739 ||| LS
) ||| S:739 E:740 ||| -RRB-
.  ||| S:740 E:742 ||| .
Studies  ||| S:742 E:750 ||| NNS
on  ||| S:750 E:753 ||| IN
efficacy  ||| S:753 E:762 ||| NN
of  ||| S:762 E:765 ||| IN
SLIT  ||| S:765 E:770 ||| NNP
in  ||| S:770 E:773 ||| IN
asthmatic  ||| S:773 E:783 ||| JJ
children  ||| S:783 E:792 ||| NNS
are  ||| S:792 E:796 ||| VBP
discordant ||| S:796 E:806 ||| JJ
,  ||| S:806 E:808 ||| ,
but  ||| S:808 E:812 ||| CC
the  ||| S:812 E:816 ||| DT
different  ||| S:816 E:826 ||| JJ
relevance  ||| S:826 E:836 ||| NN
of  ||| S:836 E:839 ||| IN
allergic  ||| S:839 E:848 ||| NN
and  ||| S:848 E:852 ||| CC
non  ||| S:852 E:856 ||| JJ
allergic  ||| S:856 E:865 ||| JJ
triggers  ||| S:865 E:874 ||| NN
of  ||| S:874 E:877 ||| IN
symptoms  ||| S:877 E:886 ||| NNS
could  ||| S:886 E:892 ||| MD
explain  ||| S:892 E:900 ||| VB
the  ||| S:900 E:904 ||| DT
discordant  ||| S:904 E:915 ||| JJ
results  ||| S:915 E:923 ||| NNS
obtained  ||| S:923 E:932 ||| VBN
in  ||| S:932 E:935 ||| IN
studies  ||| S:935 E:943 ||| NNS
on  ||| S:943 E:946 ||| IN
SLIT  ||| S:946 E:951 ||| NNP
and  ||| S:951 E:955 ||| CC
asthma ||| S:955 E:961 ||| NN
,  ||| S:961 E:963 ||| ,
particularly  ||| S:963 E:976 ||| RB
when  ||| S:976 E:981 ||| WRB
pooling  ||| S:981 E:989 ||| JJ
short  ||| S:989 E:995 ||| JJ
and  ||| S:995 E:999 ||| CC
long  ||| S:999 E:1004 ||| JJ
term  ||| S:1004 E:1009 ||| NN
studies ||| S:1009 E:1016 ||| NNS
.  ||| S:1016 E:1018 ||| .
Data  ||| S:1018 E:1023 ||| NNS
on  ||| S:1023 E:1026 ||| IN
efficacy  ||| S:1026 E:1035 ||| NN
and  ||| S:1035 E:1039 ||| CC
safety  ||| S:1039 E:1046 ||| NN
of  ||| S:1046 E:1049 ||| IN
SLIT  ||| S:1049 E:1054 ||| NNP
are  ||| S:1054 E:1058 ||| VBP
accruing  ||| S:1058 E:1067 ||| VBG
for  ||| S:1067 E:1071 ||| IN
atopic  ||| S:1071 E:1078 ||| JJ
dermatitis ||| S:1078 E:1088 ||| NN
,  ||| S:1088 E:1090 ||| ,
food  ||| S:1090 E:1095 ||| NN
allergy  ||| S:1095 E:1103 ||| NN
and  ||| S:1103 E:1107 ||| CC
latex  ||| S:1107 E:1113 ||| JJ
allergy ||| S:1113 E:1120 ||| NN
,  ||| S:1120 E:1122 ||| ,
but  ||| S:1122 E:1126 ||| CC
at  ||| S:1126 E:1129 ||| IN
the  ||| S:1129 E:1133 ||| DT
current  ||| S:1133 E:1141 ||| JJ
state  ||| S:1141 E:1147 ||| NN
of  ||| S:1147 E:1150 ||| IN
knowledge ||| S:1150 E:1159 ||| NN
,  ||| S:1159 E:1161 ||| ,
SLIT  ||| S:1161 E:1166 ||| NNP
remains  ||| S:1166 E:1174 ||| VBZ
an  ||| S:1174 E:1177 ||| DT
approach  ||| S:1177 E:1186 ||| NN
reserved  ||| S:1186 E:1195 ||| VBN
to  ||| S:1195 E:1198 ||| TO
research ||| S:1198 E:1206 ||| NN
,  ||| S:1206 E:1208 ||| ,
and  ||| S:1208 E:1212 ||| CC
no  ||| S:1212 E:1215 ||| DT
recommendations  ||| S:1215 E:1231 ||| NNS
can  ||| S:1231 E:1235 ||| MD
be  ||| S:1235 E:1238 ||| VB
established ||| S:1238 E:1249 ||| VBN
.  ||| S:1249 E:1251 ||| .
Some  ||| S:1251 E:1256 ||| DT
studies  ||| S:1256 E:1264 ||| NNS
demonstrate  ||| S:1264 E:1276 ||| VBP
that  ||| S:1276 E:1281 ||| IN
SLIT  ||| S:1281 E:1286 ||| NNP
is  ||| S:1286 E:1289 ||| VBZ
safe  ||| S:1289 E:1294 ||| JJ
in  ||| S:1294 E:1297 ||| IN
children  ||| S:1297 E:1306 ||| NNS
below  ||| S:1306 E:1312 ||| IN
5  ||| S:1312 E:1314 ||| CD
years  ||| S:1314 E:1320 ||| NNS
of  ||| S:1320 E:1323 ||| IN
age ||| S:1323 E:1326 ||| NN
,  ||| S:1326 E:1328 ||| ,
with  ||| S:1328 E:1333 ||| IN
a  ||| S:1333 E:1335 ||| DT
lower  ||| S:1335 E:1341 ||| JJR
limit  ||| S:1341 E:1347 ||| NN
of  ||| S:1347 E:1350 ||| IN
3  ||| S:1350 E:1352 ||| CD
years ||| S:1352 E:1357 ||| NNS
.  ||| S:1357 E:1359 ||| .
